Elevated levels of two tumor biomarkers, AFP and CA125, were found to predict disease worsening in people with idiopathic pulmonary arterial hypertension (IPAH) in a new study from China. “Changes in AFP over time serve as an indicator of disease alteration, enabling detection of disease progression or treatment response,”…
About 41% of pulmonary arterial hypertension (PAH) patients in a multinational survey were initially misdiagnosed, seeing an average of 2.9 physicians before getting their correct diagnosis. The non-specific nature of their disease symptoms and a lack of awareness among patients and primary care physicians contribute to this delay,…
Children with pulmonary arterial hypertension (PAH) who are started on treprostinil under the skin, or subcutaneously, at a younger age may be more likely to have better outcomes in the five years ahead, a study suggests. Starting before age 6, but not having an early response to treatment or…
Higher blood levels of the sclerostin protein were linked to cardiac abnormalities and an elevated risk of pulmonary hypertension (PH) in patients with kidney failure, according to a recent study. While sclerostin itself did not increase mortality risk, the presence of PH was a significant predictor of mortality…
Gradient Denervation Technologies has enrolled the first patient in a clinical study of an ultrasound-based catheter device for the treatment of pulmonary hypertension (PH) caused by left heart disease. The PreVail-PH2 (NCT06052072) study is evaluating the feasibility of the minimally invasive device in delivering therapeutic ultrasound energy…
Deaths around the world due to pulmonary hypertension (PH) have fallen over the past two decades, according to a new study, but 13 of the 54 countries included in the review actually saw their death rates rise. Worldwide, deaths from PH fell at an average rate of 3.2% each…
An algorithm based on artificial intelligence (AI) and machine learning may help in diagnosing pulmonary hypertension (PH), a new study shows. Its findings are particularly important for people suspected of having PH but whose disease remains uncertain using echocardiography, a noninvasive imaging method to examine heart structure and function.
Third Pole Therapeutics said it has successfully completed an early feasibility study of its portable inhaled nitric oxide (iNO) delivery device, eNOfit, allowing the company to move to larger trials for pulmonary hypertension (PH) associated with interstitial lung disease. eNOfit is designed to provide patients with mobile treatment…
Aria CV’s second-generation medical device for treating people with pulmonary arterial hypertension (PAH) — a balloon system known as the Gen 2 — has been successfully implanted in the first patient taking part in a U.S. study, according to a company press release. The…
A research project to help shed light about why people with the human immunodeficiency virus (HIV) are at higher risk for developing pulmonary hypertension (PH) was awarded a $2.67 million grant. The four-year grant from the National Heart, Lung and Blood Institute, part of the…
The Pulmonary Hypertension Association (PHA) will host a free workshop and fundraiser April 6-7 in Houston to raise awareness for pulmonary hypertension (PH) and support the greater PH community. The highlight of the weekend’s activities, which are aimed at educating, empowering, and supporting patients and caregivers, will be…
Tenax Therapeutics has secured global rights to oral and subcutaneous (under the skin) formulations of levosimendan, a potential therapy for pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF). Under a licensing agreement established with Orion Corp. in 2013, Tenax acquired developmental and commercial rights of…
Get regular updates to your inbox.